Analyzing blood samples in patients with blood cancers
Sequential Analysis in Patients With an Hemopathy
This study is testing blood samples from patients with blood cancers to see how the disease develops and changes over time.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 246 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris Academic / other |
| Locations | 1 site (Villejuif, Val de Marne) |
| Trial ID | NCT02260739 on ClinicalTrials.gov |
What this trial studies
This study focuses on understanding the complex nature of hematological malignancies by analyzing blood samples from patients with these conditions. It aims to investigate the clonal architecture of malignant cells, particularly in myeloproliferative neoplasms (MPNs), using advanced sequencing techniques. By performing sequential analyses, the study seeks to identify the initial oncogenic events and how these events contribute to disease progression and the emergence of subclones over time.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with a malignant hematological disease.
Not a fit: Patients who are legally protected or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for patients with hematological malignancies.
How similar studies have performed: Other studies utilizing next-generation sequencing to analyze clonal architecture in hematological malignancies have shown promising results, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a malignant hematological disease. * Signed written informed consent * Age and Sex : men and women aged 18 years or older * Patients affiliated to a social security system Exclusion Criteria: - Patients protected by law, in accordance with Articles L1121-L1121-5 to 8 of the Code of Public Health.
Where this trial is running
Villejuif, Val de Marne
- Gustave Roussy — Villejuif, Val de Marne, France (Recruiting)
Study contacts
- Study coordinator: Vincent RIBRAG, MD
- Email: vincent.ribrag@gustaveroussy.fr
- Phone: 0142114507
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.